New to Meducation?
Sign up
Already signed up? Log In
view moderators

PharmaceuticalPreparations

Category

Preview
1
7

HIV: Mechanisms of NRTI Resistance (Nucleoside Analogue Discrimination)

This animation explains the first mechanism of resistance of reverse transcriptase enzyme to some of NRTI drugs, known as nucleoside analogue discrimination....  
YouTube
over 7 years ago
Preview
1
63

PHARMACOLOGY; ROUTES OF DRUG ADMINISTRATION by Professor Fink

In this Video Lecture, Professor Fink identifies the major routes of administration of drugs and discusses the advantages and disadvantages of each. Referenc...  
YouTube
over 7 years ago
Preview
1
101

PHARMACOKINETICS; Absorption & Distribution of Drugs by Professor Fink

In this Video Lecture on Pharmacokinetics, Professor Fink describes the Absorption & Distribution of Drugs. The major factors affecting the systemic absorpti...  
YouTube
over 7 years ago
Preview
1
7

HIV Life Cycle and Drugs [UndergroundMed]

For more videos, check out our website at: http://videos.undergroundmed.net/  
YouTube
over 7 years ago
Preview
1
18

EAHP 2014: It doesn't matter how good the drugs are if patients don't take them

Stream EAHP 2014: It doesn't matter how good the drugs are if patients don't take them by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 7 years ago
Www.bmj
1
13

Evening the score on sex drugs: feminist movement or marketing masquerade?

Ahead of this month’s FDA workshop on patient focused drug development for women’s sexual problems, Ray Moynihan questions a campaign to get a rejected drug licensed  
bmj.com
about 7 years ago
Preview
1
10

One in five drug users 'unaware they have hepatitis C' - BBC News

About 20% of people in England who inject drugs do not know they have hepatitis C infections, according to Public Health England.  
BBC News
about 7 years ago
Preview
1
16

EAHP 2014: It doesn't matter how good the drugs are if patients don't take them

Stream EAHP 2014: It doesn't matter how good the drugs are if patients don't take them by BMJ talk medicine from desktop or your mobile device  
SoundCloud
about 7 years ago
Preview
1
10

Ballymena drugs treatment service set to close - BBC News

A County Antrim facility that works to reduce the harm caused by drugs will close early next year because of a lack of funding.  
BBC News
about 7 years ago
Preview
1
21

Concerns over use of hydroxyethyl starch solutions

Large trials have shown that hydroxyethyl starch increases the risk of death, kidney injury, and bleeding. However, an EMA review last year permitted continued use in some patients, overturning an earlier decision to withdraw the product completely. Christiane Hartog and colleagues discuss the evidence and call on doctors to avoid using starch formulations  
bmj.com
about 7 years ago
Preview
2
38

Preterm birth and the role of neuroprotection

Preterm birth remains a common complication of pregnancy and causes substantial neonatal morbidity and mortality. As improvements in the care of preterm neonates have outpaced efforts to prevent preterm birth, the numbers of survivors with neurologic sequelae that affect quality of life have increased. The main strategies to reduce the impact of neurologic complications of prematurity include prevention of preterm birth and protection of the developing fetal brain through antenatal administration of drugs. These strategies rely on a basic understanding of the intertwined pathophysiology of spontaneous preterm labor and perinatal brain injury, which will be reviewed here. The review will outline current methods for the prevention of prematurity and neuroprotection. The use of magnesium sulfate as a neuroprotective compound will be discussed, including concerns over its association with increased pediatric mortality and abnormalities in bone density.  
bmj.com
about 7 years ago
Static.www.bmj
1
24

Opioids for low back pain

Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class. More than half of regular opioid users report back pain. Rates of opioid prescribing in the US and Canada are two to three times higher than in most European countries. The analgesic efficacy of opioids for acute back pain is inferred from evidence in other acute pain conditions. Opioids do not seem to expedite return to work in injured workers or improve functional outcomes of acute back pain in primary care. For chronic back pain, systematic reviews find scant evidence of efficacy. Randomized controlled trials have high dropout rates, brief duration (four months or less), and highly selected patients. Opioids seem to have short term analgesic efficacy for chronic back pain, but benefits for function are less clear. The magnitude of pain relief across chronic non-cancer pain conditions is about 30%. Given the brevity of randomized controlled trials, the long term effectiveness and safety of opioids are unknown. Loss of long term efficacy could result from drug tolerance and emergence of hyperalgesia. Complications of opioid use include addiction and overdose related mortality, which have risen in parallel with prescription rates. Common short term side effects are constipation, nausea, sedation, and increased risk of falls and fractures. Longer term side effects may include depression and sexual dysfunction. Screening for high risk patients, treatment agreements, and urine testing have not reduced overall rates of opioid prescribing, misuse, or overdose. Newer strategies for reducing risks include more selective prescription of opioids and lower doses; use of prescription monitoring programs; avoidance of co-prescription with sedative hypnotics; and reformulations that make drugs more difficult to snort, smoke, or inject.  
bmj.com
about 7 years ago
Preview
1
43

Initial management of Parkinson’s disease

Parkinson’s disease is one of the most common neurodegenerative disorders seen in the United States and United Kingdom. The disease is characterised by two processes—cellular degeneration and the resulting biochemical deficiency of dopamine. Although these processes are inter-related, they are approached separately in the clinical setting. Currently, no proven neuroprotective or disease modifying treatment is available for Parkinson’s disease. Several agents can be used to treat the motor symptoms associated with dopamine deficiency, and it is important to choose wisely when starting treatment. Drugs can have mild, moderate, or high potency, and the patient’s goals, comorbidities, and the short and long term implications of choosing a specific agent should be taken into account when selecting the appropriate agent. Non-motor symptoms, such as depression, fatigue, and disorders of sleep and wakefulness, also need to be evaluated and treated. Research is under way to deliver dopaminergic therapy more effectively, but studies aimed at slowing or stopping disease progression have not shown promise.  
bmj.com
about 7 years ago
Preview
1
51

Asthma: pathogenesis and novel drugs for treatment

Asthma affects almost 20 million people in the United States and more than 300 million people worldwide. Of these, 10-15% have severe asthma, which is refractory to commonly available drugs. New drugs are needed because those that are currently available cannot control symptoms and exacerbations in all patients and can cause adverse reactions. In the past 10 years, there have been substantial advances in the understanding of asthma genetics, airway biology, and immune cell signaling. These advances have led to the development of small molecule therapeutics and biologic agents that may improve asthma care in the future. Several new classes of asthma drugs—including ultra long acting β agonists and modulators of the interleukin 4 (IL-4), IL-5, IL-13, and IL-17 pathways—have been evaluated in randomized controlled trials. Other new drug classes—including dissociated corticosteroids, CXC chemokine receptor 2 antagonists, toll-like receptor 9 agonists, and tyrosine kinase inhibitors—remain in earlier phases of development. Despite some preliminary efficacy data, there is insufficient evidence to make strong recommendations about the use of these newer agents. Future research on the clinical efficacy of these biologic agents, the effect of newer agents on severe asthma in pediatric patients, and the biology of non-eosinophilic and corticosteroid resistant asthma is needed to reduce the morbidity of asthma worldwide.  
bmj.com
about 7 years ago
Preview
1
20

Politics - failing to find solutions to our changing lives | Sonia Sodha

Sonia Sodha: Amazing scientific progress sees jobs changing, people living longer… Society needs to adjust its thinking  
the Guardian
about 7 years ago